Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Dapsone
Drug ID BADD_D00580
Description A sulfone active against a wide range of bacteria but mainly employed for its actions against mycobacterium leprae. Its mechanism of action is probably similar to that of the sulfonamides which involves inhibition of folic acid synthesis in susceptible organisms. It is also used with pyrimethamine in the treatment of malaria. (From Martindale, The Extra Pharmacopoeia, 30th ed, p157-8)
Indications and Usage For the treatment and management of leprosy and dermatitis herpetiformis.
Marketing Status Prescription
ATC Code D10AX05; J04BA02
DrugBank ID DB00250
KEGG ID D00592
MeSH ID D003622
PubChem ID 2955
TTD Drug ID D0MA9N
NDC Product Code 51927-0084; 70954-135; 49938-102; 65571-0021; 51552-1042; 46438-0645; 49938-101; 49452-2439; 43353-222; 16110-367; 76072-1018; 51927-4368; 53596-014; 70954-136; 58159-033; 51927-0083; 60758-670; 60429-496; 60429-495; 0904-7018; 43353-223; 14474-026; 16714-956; 71052-100; 50218-008; 51672-4197; 29967-0007; 51672-4198; 14474-038; 0023-3670; 0023-5206; 68308-342; 10695-047; 51672-1388; 45562-1120; 51927-0085; 73309-094; 13668-605; 51672-1387; 29033-036; 29033-037; 16110-526; 51672-5307; 0904-7019; 72375-0006
Synonyms Dapsone | DADPS | Sulfonyldianiline | Diaminodiphenylsulfone | Diaphenylsulfone | 4,4'-Diaminophenyl Sulfone | 4,4' Diaminophenyl Sulfone | Sulfone, 4,4'-Diaminophenyl | Sulfona | Dapson-Fatol | Disulone | Avlosulfone | Dapsoderm-X
Chemical Information
Molecular Formula C12H12N2O2S
CAS Registry Number 80-08-0
SMILES C1=CC(=CC=C1N)S(=O)(=O)C2=CC=C(C=C2)N
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
AgranulocytosisMyeloperoxidaseP05164T234717902244; 1664258; 8385460; 2856515; 1650217; 9022075; 1324677; 12060654; 11440179; 9243259; 16214851
HypersensitivityN-alpha-acetyltransferase 20P61599Not AvailableNot Available
Lupus erythematosus (incl subtypes)MyeloperoxidaseP05164T234717902244; 1664258; 8385460; 2856515; 1650217; 9022075; 1324677; 12060654; 11440179; 9243259; 16214851
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Diarrhoea07.02.01.001--
Disseminated intravascular coagulation24.01.01.010; 01.01.02.0020.000418%
Dizziness02.01.02.004; 24.06.02.007; 17.02.05.003--
Drug hypersensitivity10.01.01.001--Not Available
Dry skin23.03.03.0010.005612%
Dyspnoea22.02.01.004; 02.01.03.0020.013629%
Encephalopathy17.13.02.0010.002405%
Eosinophilia01.02.04.0010.001603%
Eosinophilic myocarditis02.04.03.002; 01.02.04.0070.000837%Not Available
Epiglottitis22.07.03.017; 11.01.13.0150.001603%Not Available
Erythema23.03.06.0010.006414%Not Available
Eye swelling06.08.03.0030.001603%Not Available
Fatigue08.01.01.002--
Feeling abnormal08.01.09.0140.003207%Not Available
Feeling hot08.01.09.0090.001603%Not Available
Fluid overload14.05.06.001; 02.05.04.0040.001603%Not Available
Gastrointestinal pain07.01.05.005--
Glucose-6-phosphate dehydrogenase deficiency14.14.03.001; 03.08.03.001; 01.06.05.001--Not Available
Granuloma23.03.15.001; 08.01.05.0010.001603%Not Available
Haemoglobin decreased13.01.05.003--Not Available
Haemolysis01.06.04.0020.004008%
Haemolytic anaemia01.06.03.0020.014431%Not Available
Hair colour changes23.02.06.0010.001603%
Headache17.14.01.001--
Hepatic fibrosis24.08.06.002; 09.01.04.0020.001603%Not Available
Hepatic steatosis14.08.04.005; 09.01.07.0030.001603%Not Available
Hepatitis09.01.07.0040.002405%Not Available
Hepatorenal syndrome20.01.03.012; 09.01.03.0070.000837%Not Available
Hepatotoxicity12.03.01.008; 09.01.07.0090.004008%Not Available
Hyperaesthesia17.02.06.0040.001603%Not Available
The 2th Page    First    Pre   2 3 4 5 6    Next   Last    Total 6 Pages